BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10084150)

  • 1. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes.
    Schwab M
    Naturwissenschaften; 1999 Feb; 86(2):71-8. PubMed ID: 10084150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic parameters of neuroblastomas.
    Westermann F; Schwab M
    Cancer Lett; 2002 Oct; 184(2):127-47. PubMed ID: 12127685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma--clinical applications of molecular parameters.
    Brodeur GM
    Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
    Schwab M
    Klin Padiatr; 1990; 202(4):197-201. PubMed ID: 2203936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic and molecular cytogenetics in neuroblastoma.
    Avet-Loiseau H; Venuat AM; Benard J; Leibovitch MP; Hartmann O; Bernheim A
    Cancer; 1995 Apr; 75(7):1694-9. PubMed ID: 8826929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
    Tsuchida Y; Hemmi H; Inoue A; Obana K; Yang HW; Hayashi Y; Kanda N; Shimatake H
    Tumour Biol; 1996; 17(2):65-74. PubMed ID: 8658015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections.
    Leong PK; Thorner P; Yeger H; Ng K; Zhang Z; Squire J
    Lab Invest; 1993 Jul; 69(1):43-50. PubMed ID: 8331897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
    Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
    Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced expression of the cellular oncogene MYCN and progression of human neuroblastoma.
    Schwab M
    Adv Enzyme Regul; 1991; 31():329-38. PubMed ID: 1877394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group.
    Lastowska M; Nacheva E; McGuckin A; Curtis A; Grace C; Pearson A; Bown N
    Genes Chromosomes Cancer; 1997 Mar; 18(3):162-9. PubMed ID: 9071568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of clinical molecular genetics. Neuroblastoma as a model tumor.
    Israel MA
    Am J Pediatr Hematol Oncol; 1986; 8(2):163-72. PubMed ID: 3526938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where pathology meets molecular biology: N-myc amplification in human neuroblastoma as a paradigm for the clinical use of an oncogene alteration.
    Schwab M
    Verh Dtsch Ges Pathol; 1994; 78():26-33. PubMed ID: 7533996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
    Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
    Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
    Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
    Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkage analysis in families with recurrent neuroblastoma.
    Perri P; Longo L; McConville C; Cusano R; Rees SA; Seri M; Conte M; Romeo G; Devoto M; Tonini GP
    Ann N Y Acad Sci; 2002 Jun; 963():74-84. PubMed ID: 12095931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
    Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
    Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.